Mineralys director granted options and RSUs

Mineralys Therapeutics director and 10% owner Srinivas Akkaraju reported equity grants.

Rhea-AI Filing Summary

Mineralys Therapeutics director and 10% owner Srinivas Akkaraju reported equity grants. On February 19, 2026, he acquired a stock option covering 8,300 shares at $0.00 per share and 6,200 shares of common stock granted for no cash consideration as restricted stock units.

The footnotes state each RSU represents one share of common stock that vests in one annual installment following the grant date, while the stock option vests in 12 substantially equal monthly installments after grant. The filing also reports indirect ownership of 5,871,018 common shares held through Samsara Opportunity Fund, L.P. and Samsara BioCapital L.P., over which Dr. Akkaraju has voting and investment power, while disclaiming beneficial ownership beyond his pecuniary interest.

Insider Trade Summary

Grant/Award: 14,500 shares

Grant/Award 3 txns

Insider AKKARAJU SRINIVAS

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	8,300	$0.00	$0.00
Grant/Award	Common Stock	6,200	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option — 8,300 contracts (Direct); Common Stock — 6,200 shares (Direct); Common Stock — 5,871,018 shares (Indirect, See footnote)

Footnotes (3)

1. F1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
2. F2. Of this amount, 588,235 shares are directly held by Samsara Opportunity Fund, L.P. (Samsara Opp LP). Samsara Opportunity Fund GP, LLC (Samsara Opp GP) is the general partner of Samsara Opp LP and may be deemed to beneficially own the securities held by Samsara Opp LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara Opp LP and, accordingly, may be deemed to beneficially own the shares held by Samsara Opp LP. Also, of this amount, 5,282,783 shares are directly held by Samsara BioCapital L.P. (Samsara LP). Samsara BioCapital GP, LLC (Samsara LLC) is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
3. F3. The stock option vests in 12 substantially equal monthly installments following the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mineralys Therapeutics (MLYS) director Srinivas Akkaraju report in this Form 4?

He reported equity awards granted on February 19, 2026, including stock options and restricted stock units. These awards increase his reported holdings through a non-cash grant, reflecting ongoing equity-based compensation rather than an open-market purchase or sale.

How many stock options were granted to Srinivas Akkaraju at Mineralys Therapeutics (MLYS)?

He received a stock option covering 8,300 shares of common stock at an exercise price of $0.00 per share. According to the footnotes, this option vests in 12 substantially equal monthly installments following the grant date, subject to continued service.

How many Mineralys Therapeutics (MLYS) shares were granted as restricted stock units?

He was granted 6,200 shares of common stock in the form of restricted stock units for no additional cash consideration. Each RSU represents a contingent right to receive one share, vesting in one annual installment following the date of grant, as described in the footnotes.

How do the vesting terms work for Srinivas Akkaraju’s Mineralys (MLYS) option and RSU grants?

The stock option vests in 12 substantially equal monthly installments after the grant date, spreading vesting over roughly one year. The restricted stock units vest in a single annual installment following the grant date, delivering shares only after vesting conditions are satisfied.

What indirect Mineralys Therapeutics (MLYS) ownership does Srinivas Akkaraju report?

He reports indirect ownership of 5,871,018 common shares held through Samsara Opportunity Fund, L.P. and Samsara BioCapital L.P. He has voting and investment power over these shares but disclaims beneficial ownership except to the extent of his pecuniary interest, according to the footnotes.

Are the reported Mineralys Therapeutics (MLYS) transactions open-market buys or sales?

No, the transactions are classified as grants or awards, not market trades. The Form 4 shows acquisitions via stock option and RSU grants at $0.00 per share, reflecting equity compensation instead of purchases or sales on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 07:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AKKARAJU SRINIVAS

(Last) (First) (Middle)

628 MIDDLEFIELD ROAD

(Street)

PALO ALTO CA 94301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		A		6,200(1)	A	$0	6,200	D
Common Stock								5,871,018	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$28.06	02/19/2026		A		8,300		(3)	02/19/2036	Common Stock	8,300	$0	8,300	D

Explanation of Responses:

1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.

2. Of this amount, 588,235 shares are directly held by Samsara Opportunity Fund, L.P. (Samsara Opp LP). Samsara Opportunity Fund GP, LLC (Samsara Opp GP) is the general partner of Samsara Opp LP and may be deemed to beneficially own the securities held by Samsara Opp LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara Opp LP and, accordingly, may be deemed to beneficially own the shares held by Samsara Opp LP. Also, of this amount, 5,282,783 shares are directly held by Samsara BioCapital L.P. (Samsara LP). Samsara BioCapital GP, LLC (Samsara LLC) is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

3. The stock option vests in 12 substantially equal monthly installments following the date of grant.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.